Author: Benzinga Newsdesk | November 10, 2025 08:03am
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.45) by 44.44 percent. This is a 132.14 percent decrease over losses of $(0.28) per share from the same period last year.